BCAB

Bioatla Inc

BCAB, USA

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

https://www.bioatla.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BCAB
stock
BCAB

Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB Defense World

Read more →
BCAB
stock
BCAB

Fibonacci Support Holding Strong in Aurionpro Solutions Limited - Equity Performance Review & Free Risk Assessment and Control earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

2

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.55

Low 1

High 3

Return on Equity (ROE)

-

Very High

50.51 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-99.18 %

Low 2%

High 10%

Investors

* Institutions hold a combined 11.29% of the total shares of Bioatla Inc

1.

Vanguard Group Inc

(3.0366%)

since

2025/06/30

2.

TANG CAPITAL MANAGEMENT LLC

(2.34%)

since

2025/06/30

3.

Renaissance Technologies Corp

(1.2844%)

since

2025/06/30

4.

Deutsche Bank AG

(0.8947%)

since

2025/06/30

5.

Geode Capital Management, LLC

(0.8383%)

since

2025/06/30

6.

BlackRock Inc

(0.819%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(0.5374%)

since

2025/06/30

8.

ADAR1 Capital Management LLC

(0.2904%)

since

2025/06/30

9.

State Street Corp

(0.2578%)

since

2025/06/30

10.

Northern Trust Corp

(0.1717%)

since

2025/06/30

11.

Two Sigma Investments LLC

(0.1407%)

since

2025/06/30

12.

Marshall Wace Asset Management Ltd

(0.1377%)

since

2025/06/30

13.

Susquehanna International Group, LLP

(0.1274%)

since

2025/06/30

14.

Magnus Financial Group LLC

(0.0804%)

since

2025/06/30

15.

Mccormack Advisors International

(0.0754%)

since

2025/06/30

16.

Alpha Cubed Investments LLC

(0.0701%)

since

2025/06/30

17.

National Asset Management Inc

(0.0511%)

since

2025/06/30

18.

UBS Group AG

(0.0504%)

since

2025/06/30

19.

COLUMBIA ADVISORY PARTNERS LLC

(0.0444%)

since

2025/06/30

20.

Commonwealth Equity Services Inc

(0.0431%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.